2022 Fiscal Year Final Research Report
Overcoming the drug resistance through muti-omics analysis in esophageal cancer
Project/Area Number |
20K07664
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Review Section |
Basic Section 50020:Tumor diagnostics and therapeutics-related
|
Research Institution | Keio University |
Principal Investigator |
|
Co-Investigator(Kenkyū-buntansha) |
松田 諭 慶應義塾大学, 医学部(信濃町), 助教 (30594725)
|
Project Period (FY) |
2020-04-01 – 2023-03-31
|
Keywords | 食道癌 / 薬剤耐性 / 炎症凝固 |
Outline of Final Research Achievements |
We aimed to elucidate the drug resistance mechanism in esophageal squamous cell carcinoma through multi-omics analysis. Using esophageal cancer cell line, we established drug resistance clone against chemotherapeutic drugs which are used in Japan as a standard treatment. Focusing on coagulation marker plasma fibrinogen, we validated its prognostic impact in esophageal cancer patients. Furthermore, based on the RNA sequence and immunogram, we identified that, in patient with increased plasma fibrinogen level, the immunosuppressive tumor microenvironment existed with accumulation of tumor associated macrophages.
|
Free Research Field |
食道癌における集学的治療
|
Academic Significance and Societal Importance of the Research Achievements |
食道扁平上皮癌は、本邦の食道癌の90%程度を占める組織型であり、化学療法の奏効が予後に直結する。その機序解明を目的とした本研究において、最新の併用レジメンへの薬剤耐性株の樹立は、今後の治療開発に有用と考えている。さらに、これまで予後不良因子として報告されてきたフィブリノゲン値と、原発巣における免疫抑制性微小環境の関連の解明は、免疫チェックポイント阻害薬が治療の中心的な役割を果たす食道癌治療の成績向上に寄与すると考えている。
|